₹641.61
Below FV▲ +42.7% against the close used
Model range ₹294.75 – ₹966.44
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Bear₹294.75Fair value₹641.61Bull₹966.44
FairClose
52-week traded range
52W low ₹378.6052W high ₹675.05
The 52-week range is measured from the stored price history, not estimated.
Trading below the consensus fair value
Rossari Biotech Limited closed at ₹449.50, 29.9% below the consensus fair value of ₹641.61 drawn from 9 valuation models.
Financial DNA score 50/100 — Good. P/E of 16.4x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
DCF Valuation
₹534.73
+19.0%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
Graham Number
₹385.86
-14.2%
√(22.5 × EPS × BVPS)
EPS=26.94, BVPS=245.63 · outside Graham range (P/E 16.4, P/B 1.8) — asset-light, treat as a rough floor
Graham Formula
₹788.00
+75.3%
EPS × (8.5 + 2g) × 6.5 ÷ FD_Rate
g=11.5%, FD=7%
P/E Fair Value
₹805.51
+79.2%
EPS × 29.9x (sector P/E)
EPS=26.94, Sector P/E=29.9x
Peter Lynch (PEG)
₹309.81
-31.1%
EPS × Growth% (PEG = 1 is fair)
EPS=26.94, g=11.5%
EV/EBITDA
₹966.44
+115.0%
(EBITDA × 15.8x − Net Debt) ÷ Shares
EBITDA=3.65B
Book Value (P/B)
₹294.75
-34.4%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=245.63, ROE=10.8%, g=6%, r=10%
Reverse DCF
₹449.50
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 4.7% | Historical: 11.5%
Margin of Safety
₹471.39
+4.9%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=628.53, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.